Moti Chapagain

1.2k total citations
26 papers, 858 citations indexed

About

Moti Chapagain is a scholar working on Infectious Diseases, Epidemiology and Molecular Biology. According to data from OpenAlex, Moti Chapagain has authored 26 papers receiving a total of 858 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Infectious Diseases, 14 papers in Epidemiology and 4 papers in Molecular Biology. Recurrent topics in Moti Chapagain's work include Tuberculosis Research and Epidemiology (12 papers), Mycobacterium research and diagnosis (12 papers) and Polyomavirus and related diseases (4 papers). Moti Chapagain is often cited by papers focused on Tuberculosis Research and Epidemiology (12 papers), Mycobacterium research and diagnosis (12 papers) and Polyomavirus and related diseases (4 papers). Moti Chapagain collaborates with scholars based in United States, South Africa and Nepal. Moti Chapagain's co-authors include Vivek R. Nerurkar, Saguna Verma, Tawanda Gumbo, Ulziijargal Gurjav, Shamshul Ansari, Rajendra Gautam, Sony Shrestha, Hari Prasad Nepal, Mukesh Kumar and Shashikant Srivastava and has published in prestigious journals such as Journal of Biological Chemistry, PLoS ONE and Clinical Infectious Diseases.

In The Last Decade

Moti Chapagain

26 papers receiving 836 citations

Peers

Moti Chapagain
Paola Goldoni Italy
Kirsten Schaffer Ireland
Sukantha Chandrasekaran United States
David M. Arana Spain
Daniela Scribano Italy
Fabrice E. Graf Switzerland
Burhan Khan United States
Bruce D. McCollister United States
Muhammad Imran Arshad Pakistan
Nadine François France
Paola Goldoni Italy
Moti Chapagain
Citations per year, relative to Moti Chapagain Moti Chapagain (= 1×) peers Paola Goldoni

Countries citing papers authored by Moti Chapagain

Since Specialization
Citations

This map shows the geographic impact of Moti Chapagain's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Moti Chapagain with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Moti Chapagain more than expected).

Fields of papers citing papers by Moti Chapagain

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Moti Chapagain. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Moti Chapagain. The network helps show where Moti Chapagain may publish in the future.

Co-authorship network of co-authors of Moti Chapagain

This figure shows the co-authorship network connecting the top 25 collaborators of Moti Chapagain. A scholar is included among the top collaborators of Moti Chapagain based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Moti Chapagain. Moti Chapagain is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Deshpande, Devyani, et al.. (2023). Ceftriaxone Efficacy for Mycobacterium avium Complex Lung Disease in the Hollow Fiber and Translation to Sustained Sputum Culture Conversion in Patients. The Journal of Infectious Diseases. 230(2). e230–e240. 3 indexed citations
2.
Chapagain, Moti, Shruti Athale, Jotam G. Pasipanodya, et al.. (2022). 1697. Dose-response Studies of the Novel Bacterial Leucyl-tRNA Synthetase Inhibitor, Epetraborole, in the Intracellular Hollow Fiber System Model of Mycobacterium avium complex Lung Disease. Open Forum Infectious Diseases. 9(Supplement_2). 2 indexed citations
3.
Chapagain, Moti, et al.. (2022). Omadacycline efficacy in the hollow fibre system model of pulmonary Mycobacterium avium complex and potency at clinically attainable doses. Journal of Antimicrobial Chemotherapy. 77(6). 1694–1705. 21 indexed citations
4.
Srivastava, Shashikant, Jann‐Yuan Wang, Gesham Magombedze, et al.. (2021). Novel Short-Course Therapy and Morphism Mapping for Clinical Pulmonary Mycobacterium kansasii. Antimicrobial Agents and Chemotherapy. 65(5). 7 indexed citations
5.
Srivastava, Shashikant, et al.. (2021). Potency of vancomycin against Mycobacterium tuberculosis in the hollow fiber system model. Journal of Global Antimicrobial Resistance. 24. 403–410. 7 indexed citations
6.
Srivastava, Shashikant, Prithvi Raj, Igor Dozmorov, et al.. (2020). sncRNA-1 Is a Small Noncoding RNA Produced by Mycobacterium tuberculosis in Infected Cells That Positively Regulates Genes Coupled to Oleic Acid Biosynthesis. Frontiers in Microbiology. 11. 1631–1631. 4 indexed citations
7.
Srivastava, Shashikant, Moti Chapagain, & Tawanda Gumbo. (2020). Effect of specimen processing, growth supplement, and different metabolic population on Mycobacterium tuberculosis laboratory diagnosis. PLoS ONE. 15(4). e0230927–e0230927. 12 indexed citations
8.
Mallikaarjun, Suresh, Moti Chapagain, T. Sasaki, et al.. (2020). Cumulative Fraction of Response for Once- and Twice-Daily Delamanid in Patients with Pulmonary Multidrug-Resistant Tuberculosis. Antimicrobial Agents and Chemotherapy. 65(1). 17 indexed citations
9.
Srivastava, Shashikant, Moti Chapagain, & Tawanda Gumbo. (2020). Effect of Specimen Processing, Growth Supplement, and Different Metabolic Population of Mycobacterium Tuberculosis Laboratory Diagnosis. A6086–A6086. 1 indexed citations
10.
Deshpande, Devyani, Shashikant Srivastava, Moti Chapagain, et al.. (2017). The discovery of ceftazidime/avibactam as an anti-Mycobacterium avium agent. Journal of Antimicrobial Chemotherapy. 72(suppl_2). i36–i42. 32 indexed citations
11.
Deshpande, Devyani, Shashikant Srivastava, Moti Chapagain, et al.. (2017). Ceftazidime-avibactam has potent sterilizing activity against highly drug-resistant tuberculosis. Science Advances. 3(8). e1701102–e1701102. 51 indexed citations
12.
Ansari, Shamshul, Hari Prasad Nepal, Rajendra Gautam, et al.. (2015). Community acquired multi-drug resistant clinical isolates of Escherichia coli in a tertiary care center of Nepal. Antimicrobial Resistance and Infection Control. 4(1). 15–15. 56 indexed citations
13.
Ansari, Shamshul, Hari Prasad Nepal, Rajendra Gautam, et al.. (2014). Childhood Septicemia in Nepal: Documenting the Bacterial Etiology and Its Susceptibility to Antibiotics. International Journal of Microbiology. 2014. 1–6. 12 indexed citations
14.
Ansari, Shamshul, Hari Prasad Nepal, Rajendra Gautam, et al.. (2014). Threat of drug resistant Staphylococcus aureus to health in Nepal. BMC Infectious Diseases. 14(1). 157–157. 69 indexed citations
15.
Huang, Zhi, et al.. (2011). Stimulation of Unprimed Macrophages with Immune Complexes Triggers a Low Output of Nitric Oxide by Calcium-dependent Neuronal Nitric-oxide Synthase. Journal of Biological Chemistry. 287(7). 4492–4502. 47 indexed citations
16.
Chapagain, Moti & Vivek R. Nerurkar. (2010). Human Polyomavirus JC (JCV) Infection of Human B Lymphocytes: A Possible Mechanism for JCV Transmigration across the Blood‐Brain Barrier. The Journal of Infectious Diseases. 202(2). 184–191. 94 indexed citations
17.
18.
Chapagain, Moti, et al.. (2008). Serotonin receptor 2A blocker (risperidone) has no effect on human polyomavirus JC infection of primary human fetal glial cells. Journal of NeuroVirology. 14(5). 448–454. 27 indexed citations
19.
Chapagain, Moti, Saguna Verma, F.J. Mercier, Richard Yanagihara, & Vivek R. Nerurkar. (2007). Polyomavirus JC infects human brain microvascular endothelial cells independent of serotonin receptor 2A. Virology. 364(1). 55–63. 64 indexed citations
20.
Chapagain, Moti, et al.. (2006). Comparison of real-time PCR and hemagglutination assay for quantitation of human polyomavirus JC. Virology Journal. 3(1). 3–3. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Paola Goldoni Breakdown of academic impact, for papers by Kirsten Schaffer Breakdown of academic impact, for papers by Sukantha Chandrasekaran Breakdown of academic impact, for papers by David M. Arana Breakdown of academic impact, for papers by Daniela Scribano Breakdown of academic impact, for papers by Fabrice E. Graf Breakdown of academic impact, for papers by Burhan Khan Breakdown of academic impact, for papers by Bruce D. McCollister Breakdown of academic impact, for papers by Muhammad Imran Arshad Breakdown of academic impact, for papers by Nadine François
Rankless by CCL
2026